An observational study in Renal Cell Carcinoma, sponsored by University Hospital, Bordeaux. Completed at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by University Hospital, Bordeaux · Observational
Multi-institutional registry on a cohort of 310 patients with biopsy-proven renal cell carcinoma treated by Radiofrequency ablation. All patients will be included consecutively and retrospectively in all centers to obtain the required number of patient followed during 5 years.
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC) is actually used in elderly patients with small renal tumors (diameter ≤ 4 cm) and presenting a high risk of surgery (due to co-morbidity) and/or reduced renal function. RFA is a minimally invasive technique, considered as an alternative to surgery to limit morbidity and to preserve kidney function. The technique is well known and has proven his efficacy for the treatment of small tumors.
An enlargement of the indications of RFA to patient without contra-indication to surgery will depend on the efficacy of the technique.
The main objective of the study is to evaluate the local efficacy of the ablation based on the technical success, and on the evaluation of local cancer recurrence over 5 years.
1,964 studies on the registry are indexed under Carcinoma, Renal Cell; 377 are open to participants now.
This study's enrollment of 310 is above the median of 146 across 360 observational studies indexed under Carcinoma, Renal Cell.
Browse Carcinoma, Renal Cell studies →University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The population concerned by the study consists in patients treated by percutaneous image-guided radiofrequency for renal tumor. The treated tumors have a diameter ≤ 4 cm characterized by computed tomography (CT) or Magnetic resonance imaging (MRI).
Exclusion Criteria:
Treated by percutaneous image-guided radiofrequency for renal tumor
Rate of local efficacy of RFA treatment
Time frame: 60 months after the RFA treatment (D0)
Overall success
Time frame: At 60 months after the RFA treatment (D0)
No recurrence of RCC
Time frame: At 60 months after the RFA treatment (D0)
Tolerance of the treatment
Time frame: At D0, 48 hours, 6, 12, 24, 36, 48 and 60 months after the RFA treatment (D0)
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux